Immucell (ICCC) Fundamental Analysis: Revenue, Earnings & Valuation

4.69 / 10

Netural

Fundamentals rate is neutral (4.7/10). Strengths include solid cash‑to‑market, favorable cost‑of‑sales ratio and healthy inventory turnover. Weak points are low fixed‑asset turnover and modest gross profit margin. Overall, the balance sheet is stable but offers limited upside.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight27.24%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value6.81

Score3/3

Weight3.36%

1M Return1.54%

Inventory turnover ratio

Value1.36

Score2/3

Weight-2.43%

1M Return-1.21%

Gross profit margin (%)

Value42.64

Score1/3

Weight-1.22%

1M Return-0.63%

PB-ROE

Value1.27

Score1/3

Weight14.46%

1M Return5.29%

Income tax / Total profit (%)

Value0.45

Score2/3

Weight2.31%

1M Return1.04%

Fixed assets turnover ratio

Value0.68

Score1/3

Weight-2.41%

1M Return-1.24%

Cost of sales ratio (%)

Value57.36

Score3/3

Weight9.98%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight33.38%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight15.33%

1M Return5.94%

Is ICCC fundamentally strong?

ICCC scores 4.69/10 on fundamentals and holds a Fair valuation at present. Backed by its -3.81% ROE, -3.76% net margin, -55.06 P/E ratio, 2.12 P/B ratio, and 53.85% earnings growth, these metrics solidify its Netural investment rating.